Comparative analysis of adverse events following immunization with DTaP vaccine in children before and after immunization schedule adjustment.

Authors

Tiane Liu, Qinghua Chen, Chunmei Ye, Jie Shen, Chang Zhu, Pai Yang, Lihua Chen, Chong Zheng

Published in

Human vaccines & immunotherapeutics. Volume 22. Issue 1. Pages 2704273. Epub Jul 20, 2026.

Abstract

This study evaluated the impact of immunization schedule adjustment - from a four-dose schedule (3, 4, 5, and 18 months of age) to a five-dose schedule (2, 4, 6, and 18 months of age, and 6y of age) - on the reporting characteristics of adverse events following immunization (AEFIs) with diphtheria, tetanus, and acellular pertussis (DTaP) vaccination in children. Surveillance data in Linping District during 2024 (pre-adjustment) and 2025 (post-adjustment) were collected. Reporting rates, symptom distributions, and dose-specific differences were compared using chi-square tests, rate ratio (RR), and sensitivity analysis. Among 18,869 doses in 2024 (91 AEFIs) and 34,549 doses in 2025 (158 AEFIs), the overall reporting rate of AEFIs did not change significantly (482.27 vs. 457.32 per 100,000 doses; RR = 0.95, 95%CI: 0.83-1.08, P = .442). Local redness and swelling (overall) showed no significant change (RR = 1.04, P = .633), with mild cases (≤2.5 cm) decreasing (RR = 0.20, P = .033) and moderate cases (2.6-5.0 cm) increasing non-significantly (RR = 1.21, P = .138). Local induration (overall) decreased significantly (RR = 0.57, P = .008), driven by moderate induration reduction (2.6-5.0 cm, RR = 0.61, P = .037). The third dose benefited most from the adjustment (RR = 0.40, P < .001). After excluding the fifth dose, reporting rate for doses 1-4 in 2025 was significantly lower than in 2024 (RR = 0.82, P = .006). The fifth dose showed the highest rate (684.84 per 100,000 doses), mostly mild reactions with no serious AEFIs. DTaP schedule adjustment did not increase overall AEFIs rates, while local induration decreased. The primary series (doses 1-4) showed a trend toward improved safety. The newly added fifth dose warrants ongoing monitoring as a key surveillance target.

PMID:
42474387
Bibliographic data and abstract were imported from PubMed on 20 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.